Unknown

Dataset Information

0

Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.

ABSTRACT:

SUBMITTER: Lucas F 

PROVIDER: S-EPMC7290091 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
| S-EPMC7316215 | biostudies-literature
Unknown The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
| S-EPMC6261467 | biostudies-literature
Unknown Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
| S-EPMC5356593 | biostudies-literature
Unknown Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication.
| S-EPMC7893066 | biostudies-literature
Unknown The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.
| S-EPMC4920022 | biostudies-literature
Unknown Ibrutinib and novel BTK inhibitors in clinical development.
| S-EPMC3751776 | biostudies-literature
Unknown Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant.
| S-EPMC5220130 | biostudies-literature
Unknown Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors.
| S-EPMC8791563 | biostudies-literature
Unknown Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.
| S-EPMC8588795 | biostudies-literature
Unknown Second cancer incidence in CLL patients receiving BTK inhibitors.
| S-EPMC7688551 | biostudies-literature